List of Figures:
Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 16
Figure 4. North America Monoclonal Antibodies Market, 2019-2030, $ bn 19
Figure 5. Impact of COVID-19 on Business 22
Figure 6. Primary Drivers and Impact Factors of North America Monoclonal Antibodies Market 24
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 27
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060 27
Figure 9. Primary Restraints and Impact Factors of North America Monoclonal Antibodies Market 29
Figure 10. Investment Opportunity Analysis 33
Figure 11. Porter’s Fiver Forces Analysis of North America Monoclonal Antibodies Market 36
Figure 12. Breakdown of North America Monoclonal Antibodies Market by Source, 2019-2030, % of Revenue 41
Figure 13. North America Addressable Market Cap in 2021-2030 by Source, Value ($ bn) and Share (%) 41
Figure 14. North America Monoclonal Antibodies Market by Source: Human, 2019-2030, $ bn 42
Figure 15. North America Monoclonal Antibodies Market by Source: Humanized, 2019-2030, $ bn 43
Figure 16. North America Monoclonal Antibodies Market by Source: Chimeric, 2019-2030, $ bn 44
Figure 17. North America Monoclonal Antibodies Market by Source: Murine, 2019-2030, $ bn 45
Figure 18. Breakdown of North America Monoclonal Antibodies Market by Category, 2019-2030, % of Sales Revenue 47
Figure 19. North America Addressable Market Cap in 2021-2030 by Category, Value ($ bn) and Share (%) 47
Figure 20. North America Monoclonal Antibodies Market by Category: Branded mAbs, 2019-2030, $ bn 48
Figure 21. North America Monoclonal Antibodies Market by Category: Biosimilar mAbs, 2019-2030, $ bn 49
Figure 22. Breakdown of North America Monoclonal Antibodies Market by Production Type, 2019-2030, % of Sales Revenue 51
Figure 23. North America Addressable Market Cap in 2021-2030 by Production Type, Value ($ bn) and Share (%) 51
Figure 24. North America Monoclonal Antibodies Market by Production Type: In Vitro Production, 2019-2030, $ bn 52
Figure 25. North America Monoclonal Antibodies Market by Production Type: In Vivo Production, 2019-2030, $ bn 53
Figure 26. Breakdown of North America Monoclonal Antibodies Market by Application, 2019-2030, % of Revenue 55
Figure 27. North America Addressable Market Cap in 2021-2030 by Application, Value ($ bn) and Share (%) 55
Figure 28. North America Monoclonal Antibodies Market by Application: Cancer, 2019-2030, $ bn 56
Figure 29. North America Monoclonal Antibodies Market by Cancer Type: Breast Cancer, 2019-2030, $ bn 58
Figure 30. North America Monoclonal Antibodies Market by Cancer Type: Colorectal Cancer, 2019-2030, $ bn 59
Figure 31. North America Monoclonal Antibodies Market by Cancer Type: Lung Cancer, 2019-2030, $ bn 60
Figure 32. North America Monoclonal Antibodies Market by Cancer Type: Ovarian Cancer, 2019-2030, $ bn 61
Figure 33. North America Monoclonal Antibodies Market by Cancer Type: Other Cancer Types, 2019-2030, $ bn 62
Figure 34. North America Monoclonal Antibodies Market by Application: Autoimmune Diseases, 2019-2030, $ bn 63
Figure 35. North America Monoclonal Antibodies Market by Application: Inflammatory Diseases, 2019-2030, $ bn 64
Figure 36. North America Monoclonal Antibodies Market by Application: Infectious Diseases, 2019-2030, $ bn 65
Figure 37. North America Monoclonal Antibodies Market by Application: Other Applications, 2019-2030, $ bn 66
Figure 38. Breakdown of North America Monoclonal Antibodies Market by End User, 2019-2030, % of Revenue 68
Figure 39. North America Addressable Market Cap in 2021-2030 by End User, Value ($ bn) and Share (%) 68
Figure 40. North America Monoclonal Antibodies Market by End User: Hospitals, 2019-2030, $ bn 69
Figure 41. North America Monoclonal Antibodies Market by End User: Research Institutes, 2019-2030, $ bn 70
Figure 42. North America Monoclonal Antibodies Market by End User: Other End Users, 2019-2030, $ bn 71
Figure 43. Breakdown of North America Monoclonal Antibodies Market by Country, 2019 and 2030, % of Revenue 73
Figure 44. Contribution to North America 2021-2030 Cumulative Market by Country, Value ($ bn) and Share (%) 74
Figure 45. U.S. Monoclonal Antibodies Market, 2019-2030, $ bn 76
Figure 46. Canada Monoclonal Antibodies Market, 2019-2030, $ bn 78
Figure 47. Monoclonal Antibodies Market in Mexico, 2019-2030, $ bn 80
Figure 48. Growth Stage of North America Monoclonal Antibodies Industry over the Forecast Period 82
North America monoclonal antibodies market is projected to grow by 10.4% annually in the forecast period and reach $133.4 billion by 2030, driven by the increasing incidences of new cancer cases and other diseases, growth in geriatric population, increasing pharmaceutical R&D spending, upsurge in healthcare expenditure, and the rising adoption of cost-efficient biosimilar monoclonal antibodies. Highlighted with 24 tables and 48 figures, this 102-page report “North America Monoclonal Antibodies (mAbs) Market 2020-2030 by Source (Human, Humanized, Chimeric, Murine), Category (Branded, Biosimilar), Production Type (In Vitro, In Vivo), Application (Cancer, Autoimmune, Inflammatory), End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America monoclonal antibodies market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19). In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America monoclonal antibodies market in every aspect of the classification from perspectives of Source, Category, Production Type, Application, End User, and Country. Based on Source, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Human • Humanized • Chimeric • Murine Based on Category, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Branded mAbs • Biosimilar mAbs Based on Production Type, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • In Vitro Production • In Vivo Production Based on Application, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Cancer • Breast Cancer • Colorectal Cancer • Lung Cancer • Ovarian Cancer • Other Cancer Types • Autoimmune Diseases • Inflammatory Diseases • Infectious Diseases • Other Applications By End User, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Hospitals • Research Institutes • Other End Users Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2019-2030. The breakdown of key national markets by Source, Application, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): Abbott Laboratories AbbVie, Inc. Amgen Inc. AstraZeneca plc Bayer AG Bristol-Myers Squibb Company Eli Lilly F. Hoffmann-La Roche Ltd. GlaxoSmithKline Plc Johnson & Johnson Merck & Co., Inc. Mylan N.V Norvatis AG Pfizer Sanofi S.A. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More